The CFRI CF Community Voices Podcast

Food Insecurity and CF: Challenges and Resources

It is estimated that over 25% of CF community members face food insecurity. In this webinar, recorded on Wednesday, September 1, a panel of personal and professional experts will discuss this issue, while sharing tips and resources for individuals facing this challenge. Hear from Georgia Brown, SNAP participant who lives with CF, Tiffany Raffino, LCSW, CF social worker at UCSF, and Katherine Jacobs, MPH, RDN, of the Food Research and Action Center for an engaging discussion, with Q and A from the audience.

Click here to view Tiffany Raffino's slides: https://www.cfri.org/wp-content/uploads/2021/09/Food-Security-Tiffany-Raffino.pdf

Click here to view Katherine Jacobs' slides: https://www.cfri.org/wp-content/uploads/2021/09/CFRI-Podcast_Food-Insecurity-Katherine-Jacobs.pdf

Click here to let us know what you think of this podcast:

https://www.surveymonkey.com/r/TMRP766

CF Community Voices is sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, and Viatris.

Food Insecurity and CF: Challenges and Resources (Audio)

It is estimated that over 25% of CF community members face food insecurity. In this webinar, recorded on Wednesday, September 1, a panel of personal and professional experts will discuss this issue, while sharing tips and resources for individuals facing this challenge. Hear from Georgia Brown, SNAP participant who lives with CF, Tiffany Raffino, LCSW, CF social worker at UCSF, and Katherine Jacobs, MPH, RDN, of the Food Research and Action Center for an engaging discussion, with Q and A from the audience.

Click here to view Tiffany Raffino's slides: https://www.cfri.org/wp-content/uploads/2021/09/Food-Security-Tiffany-Raffino.pdf

Click here to view Katherine Jacobs' slides: https://www.cfri.org/wp-content/uploads/2021/09/CFRI-Podcast_Food-Insecurity-Katherine-Jacobs.pdf

Click here to let us know what you think of this podcast:

https://www.surveymonkey.com/r/TMRP766

CF Community Voices is sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, and Viatris.

Q&A on CF and COVID-19 with Richard Moss, MD

Dr. Rick Moss, Professor Emeritus of Pediatrics at Stanford University and retired Director of the Stanford Cystic Fibrosis Center, answers follow-up questions on his presentation "Getting to the After Times: CF and COVID in Year 2" at CFRI's 34th National CF Education Conference. The Q&A was recorded on August 6, 2021.

Q&A on CF and COVID-19 with Richard Moss, MD (Audio)

Dr. Rick Moss, Professor Emeritus of Pediatrics at Stanford University and retired Director of the Stanford Cystic Fibrosis Center, answers follow-up questions on his presentation "Getting to the After Times: CF and COVID in Year 2" at CFRI's 34th National CF Education Conference. The Q&A was recorded on August 6, 2021.

Role of Disrupted Airway-Surface Liquid (ASL) pH Regulation in Small Airways in CF Lung Disease Pathogenesis - Xiaopeng Li, PhD

Dr. Xiaopeng Li, Associate Professor in the Department of Pediatrics and Human Development in the College of Human Medicine at Michigan State University, presents research on impaired mucociliary transport and a lower airway-surface liquid (ASL) pH in CF small airways, and potential novel therapeutic target for small airways diseases. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

A Multi-‘Omic Approach to Evaluate Concurrent Sinus and Pulmonary Disease in Cystic Fibrosis - Keehoon Lee, PhD

Dr. Keehoon Lee, a postdoctoral scholar at the Pathogen and Microbiome Institute at Northern Arizona University, presents research on the microbial composition of upper and lower CF airways in patients with chronic rhinosinusitis. He highlights the relationship between microbiome composition and host response, such as specific gene expressions and their functions in disease control. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advancing the GI Frontier for People with CF - Steven Freedman, MD, PhD

Dr. Steven Freedman, Director of the Pancreas Center at Beth Israel Deaconess Medical Center, Chief of the Division of Translational Research, and Professor of Medicine at Harvard Medical School, highlights the multiple GI manifestations that accompany cystic fibrosis. The presentation also discusses current trials and efforts to create best practice guidelines for clinicians. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Advances in Phage Therapy as a Treatment for Cystic Fibrosis - Benjamin Chan, PhD; Jon Koff, MD

Dr. Benjamin Chan, an Associate Research Scientist in the Department of Ecology and Evolutionary Biology at Yale University, and Dr. Jon Koff, Director of the Adult Cystic Fibrosis Program at Yale University, give a comprehensive overview on recent progress in phage therapy as a treatment for CF, including the development of a clinical trial to investigate the safety and efficacy of a nebulized personalized phage therapy approach and the establishment of a Center for Bacteriophage Research and Therapy at Yale. This presentation was part of CFRI's Virtual 34th National CF Education Conference on July 31, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

Role of Disrupted Airway-Surface Liquid (ASL) pH Regulation in Small Airways in CF Lung Disease Pathogenesis - Xiaopeng Li, PhD (Audio)

Dr. Xiaopeng Li, Associate Professor in the Department of Pediatrics and Human Development in the College of Human Medicine at Michigan State University, presents research on impaired mucociliary transport and a lower airway-surface liquid (ASL) pH in CF small airways, and potential novel therapeutic target for small airways diseases. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.

A Multi-‘Omic Approach to Evaluate Concurrent Sinus and Pulmonary Disease in Cystic Fibrosis - Keehoon Lee, PhD (Audio)

Dr. Keehoon Lee, a postdoctoral scholar at the Pathogen and Microbiome Institute at Northern Arizona University, presents research on the microbial composition of upper and lower CF airways in patients with chronic rhinosinusitis. He highlights the relationship between microbiome composition and host response, such as specific gene expressions and their functions in disease control. This presentation was part of CFRI's Virtual 34th National CF Education Conference on August 1, 2021.

CFRI's 34th National CF Education Conference was sponsored by Vertex Pharmaceuticals, Genentech, Gilead Sciences, Chiesi USA, AbbVie, and Ionis Pharmaceuticals.